Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
2006-05-30
2006-05-30
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211150, C514S227800, C514S234200, C514S263200, C514S263220, C514S263300, C514S263400, C540S481000, C540S492000, C540S524000, C544S061000, C544S118000, C544S264000, C544S265000, C544S277000
Reissue Patent
active
RE039112
ABSTRACT:
The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action.A purine compound represented by the formula (I), its pharmacologically acceptable salt or hydrates thereof has an adenosine A2 receptor antagonistic action and is useful for prevention or therapy of diabetes mellitus and diabetic complications. In addition, adenosine A2 receptor antagonists having different structures from those of the compounds described above, for example KW6002, are also effective for prevention or therapy of diabetes mellitus and diabetic complications.In the formula, W is —CH2CH2—, or —CH═CH— or —C≡C—; R1is:(in the formula, X is hydrogen atom, hydroxyl group, a lower alkyl group, a lower alkoxy group, etc.; and R5and R6are the same as or different from each other and each represents hydrogen atom, a lower alkyl group, a cycloalkyl group, etc.) and the like; R2is an amino group, etc. which maybe substituted with a lower alkyl group, etc.; R3is a cycloalkyl group, an optionally substituted aryl group, etc.; and R4is a lower alkyl group etc.
REFERENCES:
patent: 5256398 (1993-10-01), McAfee et al.
patent: 5861396 (1999-01-01), Niewohner et al.
patent: 5861404 (1999-01-01), Niewohner et al.
patent: 6511984 (2003-01-01), Elliott
patent: 5-222045 (1993-08-01), None
patent: 9-124648 (1997-05-01), None
patent: WO 9206976 (1992-04-01), None
patent: WO 9701551 (1997-01-01), None
patent: WO 9746560 (1997-12-01), None
Zhange, Metabolism 46, 273 (1997).
Sonnenberg, Curr. Opinion Nephrol. Hypertens. 7, 551 (1998).
Seyama, JACS 110, 2192 (1988).
Zielenkiewicz et al., Journal of Thermal Analysis, vol. 43, pp. 775-779 □□(1995).
Tanji et al., Chemical & Pharmaceutical Bulletin, vol. 36, No. 6, pp. 1935-1941.
Legraverend et a;., Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 793-798 (1998).
Camaion et al., Bioorganic & Medicinal Chemistry Letters, vol. 6, pp. 523-533 (1998).
Asano Osamu
Harada Hitoshi
Horizoe Tatsuo
Hoshino Yorihisa
Inoue Takashi
Berch Mark L.
Birch & Stewart Kolasch & Birch, LLP
Eisai Co. Ltd.
LandOfFree
Purine derivatives and adenosine A2 receptor antagonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purine derivatives and adenosine A2 receptor antagonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine derivatives and adenosine A2 receptor antagonists... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3573867